Dumot Chloe, Mantziaris Georgios, Dayawansa Sam, Brantley Carson, Lee Cheng-Chia, Yang Huai-Che, Peker Selcuk, Samanci Yavuz, Mathieu David, Tourigny Jean-Nicolas, Martinez Moreno Nuria, Martinez Alvarez Roberto, Chytka Thomas, Liscak Roman, Speckter Herwin, Lazo Erwin, Brito Anderson, Picozzi Piero, Franzini Andrea, Alzate Juan, Mashiach Elad, Bernstein Kenneth, Kondziolka Douglas, Tripathi Manjul, Bowden Greg N, Warnick Ronald E, Sheehan Darrah, Sheehan Kimball, Fuentes Angelica, Jane John A, Vance Mary Lee, Sheehan Jason P
Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA.
Department of Neurological Surgery, Hospices Civils de Lyon, Lyon, France.
Neuro Oncol. 2024 Dec 5;26(12):2328-2338. doi: 10.1093/neuonc/noae133.
A higher risk of secondary brain tumor, carotid stenosis, and stroke has been reported after conventional sella irradiation for pituitary neuroendocrine tumors (PitNET). Stereotactic radiosurgery (SRS), which is a more focused approach, is now increasingly used instead. The aim was to assess the risk of secondary brain tumor, carotid stenosis/occlusion, and stroke after SRS.
In this multicentric retrospective study, 2254 patients with PitNET were studied, 1377 in the exposed group, and 877 in the control group.
There were 9840.1 patient-years at risk for the SRS and 5266.5 for the control group. The 15-year cumulative probability of secondary intracranial tumor was 2.3% (95% CI: 0.5%, 4.1%) for SRS and 3.7% (95% CI: 0%, 8.7%) for the control group (P = .6), with an incidence rate of 1.32 per 1000 and 0.95 per 1000, respectively. SRS was not associated with an increased risk of tumorigenesis when stratified by age (HR: 1.59 [95% CI: 0.57, 4.47], Pp = .38). The 15-year probability of new carotid stenosis/occlusion was 0.9% (95% CI: 0.2, 1.6) in the SRS and 2% (95% CI: 0, 4.4) in the control group (P = .8). The 15-year probability of stroke was 2.6% (95% CI: 0.6%, 4.6%) in the SRS and 11.1% (95% CI: 6%, 15.9%) in the control group (P < .001). In Cox multivariate analysis stratified by age, SRS (HR 1.85 [95% CI:0.64, 5.35], P = .26) was not associated with risk of new stroke.
No increased risk of long-term secondary brain tumor, new stenosis or occlusion, and stroke was demonstrated in the SRS group compared to the control in this study with imaging surveillance.
据报道,垂体神经内分泌肿瘤(PitNET)接受传统鞍区放疗后,发生继发性脑肿瘤、颈动脉狭窄和中风的风险较高。立体定向放射外科(SRS)是一种更具针对性的方法,现在越来越多地被采用。本研究旨在评估SRS后发生继发性脑肿瘤、颈动脉狭窄/闭塞和中风的风险。
在这项多中心回顾性研究中,对2254例PitNET患者进行了研究,其中1377例为暴露组,877例为对照组。
SRS组的风险患者年数为9840.1,对照组为5266.5。SRS组15年继发性颅内肿瘤累积概率为2.3%(95%CI:0.5%,4.1%),对照组为3.7%(95%CI:0%,8.7%)(P = 0.6),发病率分别为每1000人1.32例和每1000人0.95例。按年龄分层时,SRS与肿瘤发生风险增加无关(HR:1.59 [95%CI:0.57,4.47],Pp = 0.38)。SRS组15年新发颈动脉狭窄/闭塞概率为0.9%(95%CI:0.2,1.6),对照组为2%(95%CI:0,4.4)(P = 0.8)。SRS组15年中风概率为2.6%(95%CI:0.6%,4.6%),对照组为11.1%(95%CI:6%,15.9%)(P < 0.001)。在按年龄分层的Cox多变量分析中,SRS(HR 1.85 [95%CI:0.64,5.35],P = 0.26)与新发中风风险无关。
在本影像监测研究中,与对照组相比,SRS组未显示长期继发性脑肿瘤、新的狭窄或闭塞以及中风风险增加。